ClinicalTrials.gov record
Completed Phase 3 Interventional

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

ClinicalTrials.gov ID: NCT04819269

Public ClinicalTrials.gov record NCT04819269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT04819269
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sylentis, S.A.
Industry
Enrollment
203 participants

Conditions and interventions

Interventions

  • Tivanisiran sodium ophthalmic solution Drug
  • Vehicle ophthalmic solution Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 24, 2021
Primary completion
Dec 10, 2023
Completion
Dec 10, 2023
Last update posted
Feb 19, 2024

2021 – 2023

United States locations

U.S. sites
39
U.S. states
18
U.S. cities
38
Facility City State ZIP Site status
Sylentis Investigative Site Birmingham Alabama 35294
Sylentis Investigative Site Dothan Alabama 36301
Sylentis Investigative Site Scottsdale Arizona 85254
Sylentis Investigative Site Garden Grove California 92843
Sylentis Investigative Site Glendale California 91204
Sylentis Investigative Site Los Angeles California 90013
Sylentis Investigative Site Newport Beach California 92663
Sylentis Investigative Site Rancho Cordova California 95670
Sylentis Investigative Site San Diego California 92122
Sylentis Investigative Site Torrance California 90505
Sylentis Investigative Site Aurora Colorado 80045
Sylentis Investigative Site Colorado Springs Colorado 80907
Sylentis Investigative Site Littleton Colorado 80120
Sylentis Investigative Site Jacksonville Florida 32256
Sylentis Investigative Site Largo Florida 33773
Sylentis Investigative Site Miami Florida 33136
Sylentis Investigative Site Ormond Beach Florida 32174
Sylentis Investigative Site Tampa Florida 33603
Sylentis Investigative Site Atlanta Georgia 30339
Sylentis Investigative Site Morrow Georgia 30260
Sylentis Investigative Site Carmel Indiana 46290
Sylentis Investigative Site Waltham Massachusetts 02451
Sylentis Investigative Site Ypsilanti Michigan 48197
Sylentis Investigative Site Kansas City Missouri 64111
Sylentis Investigative Site St Louis Missouri 63131
Sylentis Investigative Site Washington Missouri 63090
Sylentis Investigative Site Asheville North Carolina 28803
Sylentis Investigative Site High Point North Carolina 27262
Sylentis Investigative Site Fargo North Dakota 58103
Sylentis Investigative Site Cleveland Ohio 44115
Sylentis Investigative Site Columbus Ohio 43215
Sylentis Investigative Site Cranberry Township Pennsylvania 16066
Sylentis Investigative Site Rapid City South Dakota 57701
Sylentis Investigative Site Memphis Tennessee 38103
Sylentis Investigative Site Nashville Tennessee 37215
Sylentis Investigative Site El Paso Texas 79902
Sylentis Investigative Site Houston Texas 77030
Sylentis Investigative Site Houston Texas 77034
Sylentis Investigative Site Falls Church Virginia 22042

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04819269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 19, 2024 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04819269 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →